Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications

Bariatric surgery is increasingly seen as a treatment option for patient with type 2 diabetes (T2DM) and severe complex obesity (SCO). There is however no consensus on how to manage this cohort preoperatively and postoperatively. Patients with T2DM having cardiac surgery benefit from glycaemic optimisation prior to surgery. National Health Service Diabetes in the United Kingdom recommends that glucose is optimised prior to all elective surgery. However, bariatric surgery such as gastric bypass (RYGB) is distinct from general surgery. Glycaemic control improves immediately after RYGB and thus all T2DM patients need a review of their glucose lowering medications postoperatively. Preoperatively most bariatric centres use a low calorie diet (LCD) which improved glycaemic control and may predisposed patients using insulin or sulphonylureas to risks of hypoglycaemia. There are no protocols and consensus among bariatric centres on how best to manage patients with T2DM preoperatively and postoperatively. Moreover patients with difficult to control T2DM are at risk of microvascular complications of diabetes. So far, there is little evidence on the impact of bariatric surgery on diabetes nephropathy, retinopathy and neuropathy. In conclusion, bariatric surgery improves glycaemic control; however, there are limited studies, and no guidelines on how to manage patients with T2DM pre and postoperatively. Given the increasing proportion of T2DM patients referred for bariatric surgery, there is a need to review current practice on how to manage these patients in the short term and long term with a specific focus on improving end organ damage such as retinopathy, neuropathy and nephropathy.

Saved in:
Bibliographic Details
Main Authors: Chuah,L. L., le Roux,Carel W.
Format: Digital revista
Language:English
Published: Grupo Arán 2013
Online Access:http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112013000800004
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:scielo:S0212-16112013000800004
record_format ojs
spelling oai:scielo:S0212-161120130008000042013-09-17Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complicationsChuah,L. L.le Roux,Carel W. Diabetes Obesity Bariatric surgery Microvascular complications Bariatric surgery is increasingly seen as a treatment option for patient with type 2 diabetes (T2DM) and severe complex obesity (SCO). There is however no consensus on how to manage this cohort preoperatively and postoperatively. Patients with T2DM having cardiac surgery benefit from glycaemic optimisation prior to surgery. National Health Service Diabetes in the United Kingdom recommends that glucose is optimised prior to all elective surgery. However, bariatric surgery such as gastric bypass (RYGB) is distinct from general surgery. Glycaemic control improves immediately after RYGB and thus all T2DM patients need a review of their glucose lowering medications postoperatively. Preoperatively most bariatric centres use a low calorie diet (LCD) which improved glycaemic control and may predisposed patients using insulin or sulphonylureas to risks of hypoglycaemia. There are no protocols and consensus among bariatric centres on how best to manage patients with T2DM preoperatively and postoperatively. Moreover patients with difficult to control T2DM are at risk of microvascular complications of diabetes. So far, there is little evidence on the impact of bariatric surgery on diabetes nephropathy, retinopathy and neuropathy. In conclusion, bariatric surgery improves glycaemic control; however, there are limited studies, and no guidelines on how to manage patients with T2DM pre and postoperatively. Given the increasing proportion of T2DM patients referred for bariatric surgery, there is a need to review current practice on how to manage these patients in the short term and long term with a specific focus on improving end organ damage such as retinopathy, neuropathy and nephropathy.Grupo AránNutrición Hospitalaria v.28 suppl.2 20132013-01-01journal articletext/htmlhttp://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112013000800004en
institution SCIELO
collection OJS
country España
countrycode ES
component Revista
access En linea
databasecode rev-scielo-es
tag revista
region Europa del Sur
libraryname SciELO
language English
format Digital
author Chuah,L. L.
le Roux,Carel W.
spellingShingle Chuah,L. L.
le Roux,Carel W.
Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
author_facet Chuah,L. L.
le Roux,Carel W.
author_sort Chuah,L. L.
title Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
title_short Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
title_full Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
title_fullStr Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
title_full_unstemmed Management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
title_sort management of patients with type 2 diabetes before and after bariatric surgery: evolution and microvascular complications
description Bariatric surgery is increasingly seen as a treatment option for patient with type 2 diabetes (T2DM) and severe complex obesity (SCO). There is however no consensus on how to manage this cohort preoperatively and postoperatively. Patients with T2DM having cardiac surgery benefit from glycaemic optimisation prior to surgery. National Health Service Diabetes in the United Kingdom recommends that glucose is optimised prior to all elective surgery. However, bariatric surgery such as gastric bypass (RYGB) is distinct from general surgery. Glycaemic control improves immediately after RYGB and thus all T2DM patients need a review of their glucose lowering medications postoperatively. Preoperatively most bariatric centres use a low calorie diet (LCD) which improved glycaemic control and may predisposed patients using insulin or sulphonylureas to risks of hypoglycaemia. There are no protocols and consensus among bariatric centres on how best to manage patients with T2DM preoperatively and postoperatively. Moreover patients with difficult to control T2DM are at risk of microvascular complications of diabetes. So far, there is little evidence on the impact of bariatric surgery on diabetes nephropathy, retinopathy and neuropathy. In conclusion, bariatric surgery improves glycaemic control; however, there are limited studies, and no guidelines on how to manage patients with T2DM pre and postoperatively. Given the increasing proportion of T2DM patients referred for bariatric surgery, there is a need to review current practice on how to manage these patients in the short term and long term with a specific focus on improving end organ damage such as retinopathy, neuropathy and nephropathy.
publisher Grupo Arán
publishDate 2013
url http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0212-16112013000800004
work_keys_str_mv AT chuahll managementofpatientswithtype2diabetesbeforeandafterbariatricsurgeryevolutionandmicrovascularcomplications
AT lerouxcarelw managementofpatientswithtype2diabetesbeforeandafterbariatricsurgeryevolutionandmicrovascularcomplications
_version_ 1755936743226343424